The Assault on Generics

For nearly as long as the Sunshine State has attracted retirees, it has been a rich market for DuPont Pharmaceuticals. The company sells close to $50 million of its blood thinner Coumadin to heart and stroke patients in Florida each year, and it had the market all to itself until 1997. Then the U.S. Food and Drug Administration approved Barr Laboratories' generic version, and suddenly DuPont's monopoly was threatened.

But for three years running, DuPont has managed to shut Barr out. This month it quashed a bill that would have made it easier for Florida patients to get generic substitutes for...

Want the full story?

Subscribe Now


Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!